HC Wainwright reissued their buy rating on shares of PDS Biotechnology (NASDAQ:PDSB – Free Report) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a $21.00 price target on the stock. Several other brokerages have also recently commented on PDSB. B. Riley decreased their price target on shares of […]

HC Wainwright reiterated their buy rating on shares of BioNTech (NASDAQ:BNTX – Free Report) in a research note released on Monday, Benzinga reports. HC Wainwright currently has a $113.00 price objective on the stock. A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. upgraded BioNTech from an underweight […]

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS – Free Report) in a research note published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. GOSS has been the topic of several other research reports. The Goldman Sachs Group reiterated a buy rating and […]

HC Wainwright restated their buy rating on shares of IO Biotech (NASDAQ:IOBT – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $12.00 target price on the stock. Other research analysts have also recently issued reports about the stock. Piper Sandler reiterated an overweight rating and […]

HC Wainwright reaffirmed their buy rating on shares of Replimune Group (NASDAQ:REPL – Free Report) in a report issued on Monday, Benzinga reports. The firm currently has a $17.00 price objective on the stock. Several other research analysts have also recently weighed in on REPL. Wedbush reissued an outperform rating and issued a $16.00 price […]